Pierre-Alexandre Teulié | CEO
ODDIFACT

Reimagining Rare Disease Treatments' Approach Pierre-Alexandre Teulié, co-founder and CEO of ODDIFACT,  forged through senior roles at Procter & Gamble, Nestlé, and Carrefour, and recognized as a Young Global Leader by the World Economic Forum in 2011, has spent three decades mastering one principle above all others: when a system is structurally dysfunctional, don't improve it — reimagine it. A age of 40 Teulié was diagnosed with a rare disease. He then discovered what 300 to 400 million people worldwide already know: that of the 7,000 identified rare diseases, the vast majority have no approved treatment. Not for lack of science, but because the conventional drug development model is not sustainable for small patient populations. In 2024, he co-founded ODDIFACT with AI entrepreneur Mehdi-Alexandre Manga to change that. The company's proprietary AI algorithm mines off-label drug data and untapped clinical research to identify repositioning opportunities for existing biologics, converting them into Orphan Drug Designation submissions — the key regulatory gateway for rare disease treatments. The results are striking. In less than 2 years, ODDIFACT secured more FDA Orphan Drug Designations than any other company, sustaining up to three submissions per month in 2025. The ambition: 50 new treatments and 500,000 patients reached by 2030. Business Worldwide Magazine named Teulié "Most Innovative CEO in Rare Disease Research & Treatment Development" in 2025. Behind every submission is a patient who has been waiting for years. Teulié was once that patient — and he has not forgotten it.